AMTYMSO
LIVE

Serial Number

99222190

Owner

H. Lundbeck A/S

Attorney

Maren Perry

Filing Date

Jun 6, 2025

Add to watchlist:

No watchlists yet
View on USPTO

AMTYMSO Trademark

Serial Number: 99222190 • Registration: 8108489

AMTYMSO is a trademark filed by H. Lundbeck A/S on June 6, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

H. Lundbeck A/S (398 trademarks)

Ottiliavej 9
DK-2500 Copenhagen-Valby , DK

Entity Type: 03

Trademark Details

Filing Date

June 6, 2025

Registration Date

January 20, 2026

Published for Opposition

December 2, 2025

Goods & Services

Sanitary preparations for medical purposes; dietetic preparations adapted for medical purposes; vaccines; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases of, generated from and affecting the central nervous system; pharmaceutical preparations and substances for treatment of central nervous system disorders; central nervous system stimulants; pharmaceutical preparations and substances for the diagnosis, prevention and treatment of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune diseases and disorders; pharmaceutical preparations and substances for diagnosis, prevention and treatment of dementia, Alzheimer's disease, depression, psychosis, anxiety, Lennox-Gastaut disease, epilepsy, Dravet Syndrome, Developmental and Epileptic Encephalopathy (DEE), alpha-synucleinopathies, Multiple System Atrophy (MSA), dementia with Lewy bodies, rapid eye movement (REM) sleep behavior syndrome, porphyria, Huntington's disease, insomnia, Parkinson's disease, sclerosis, multiple sclerosis, schizophrenia, bipolar disorder, cancer, pain, migraine, headache, Horton's headache, traumatic brain injury, post-traumatic brain injury, dizziness, seizures, stroke, cognitive impairment, cognitive disorders and diseases, mood disorders, falls, movement disorders and diseases, tremor, agitation, mania, aggression, autism, melancholia, Obsessive Compulsive Disorder (OCD), Tourette's syndrome, restlessness, akathisia, fatigue, somnolence, nausea, Cushing's disease, Adrenogenital syndrome (AGS), narcolepsy, Post-Traumatic Stress Disorder (PTSD), Attention Deficit Hyperactivity Disorder (ADHD), Progressive Supranuclear Palsy (PSP), Thyroid Associated Orbitopathy (TAO), Graves Orbitopathy, Hashimoto's Thyroiditis, alcoholism and addiction; diagnostic agents and preparations for medical purposes; chemical substances for diagnostic and medical purposes, namely, chemical reagents for medical use, diagnostic chemical reagents for medical purposes; medical diagnostic reagents

Medical apparatus, namely, infusion and injection devices for administering drugs; syringes, intravenous bags sold empty for intravenous therapy, intravenous (IV) feeding tubes, intravenous (IV) infusion pumps, and intravenous (IV) catheters; injection devices for administering drugs, syringes and needles for injections and medical purposes; apparatus and instruments for diagnostic purposes, namely, dosage management dispensers for medicines and containing downloadable and recorded software for medical information management for use in web-based physical and psychological examination and assessment of patients at a distance and at a clinic; medical devices and instruments for the diagnosis, administration, monitoring, assessment, control and examination of psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases; integrated medical systems comprising of medical instruments for diagnostics and examination of patients and downloadable computer software for processing patient intake and communications and information management, all for use in the physical and psychological and neurological examination and assessment of patients and clients; integrated medical systems comprised of medical devices and instruments for treating central nervous system diseases and disorders and psychiatric, neurological, neurohormonal, neurogenetic, neuroendocrinological and autoimmune disorders and diseases, all for the purposes of management, measurement, monitoring, evaluation, control, collection, storage, transmission and examination of patient and client data and information; medical instruments for providing medication administering information, guidance, and management in the nature of devices for delivery and administering of medicines and infusion pumps

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 20, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 20, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 2, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 2, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 26, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 5, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 5, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 5, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 5, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 5, 2025 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 3, 2025 GNFN
FINAL REFUSAL E-MAILED
Nov 3, 2025 GNFR
FINAL REFUSAL WRITTEN
Nov 3, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 24, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 24, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 24, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 28, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jun 28, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jun 28, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 24, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 6, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 6, 2025 NWOS
NEW APPLICATION ENTERED
Jun 6, 2025 NWAP